Please enable JavaScript to continue using this application.

Compare $SNDX vs $TSHA | Chartloom

Compare

$SNDX vs $TSHA

Syndax Pharmaceuticals Inc · Taysha Gene Therapies Inc

SNDX

Syndax Pharmaceuticals Inc

TSHA

Taysha Gene Therapies Inc

Compare $SNDX vs $TSHA

Comparing Syndax Pharmaceuticals Inc and Taysha Gene Therapies Inc

SNDXSyndax Pharmaceuticals Inc

TSHATaysha Gene Therapies Inc

SNDXSyndax Pharmaceuticals Inc

Market cap

$1.51B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

222.7%

YTD performance

-20.2%

52W performance

3.0%

FCF yield

-14.7%

TSHATaysha Gene Therapies Inc

Market cap

$1.44B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

664.56x

Rev growth (TTM)

-32.3%

YTD performance

-14.5%

52W performance

-11.3%

FCF yield

-9.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

SNDX

TSHA

Detailed metrics comparison

SNDX

Syndax Pharmaceuticals Inc

TSHA

Taysha Gene Therapies Inc

Market Cap

SNDX$1.51B

TSHA$1.44B

Enterprise Value

SNDX$1.76B

TSHA$1.03B

Price

SNDX$16.99

TSHA$4.49

P/E Ratio

SNDXN/A

TSHAN/A

P/S Ratio

SNDX5.97x

TSHA261.77x

EV/Sales

SNDX6.97x

TSHA187.75x

EV/EBITDA

SNDX1,613.51x

TSHA0.00x

P/B Ratio

SNDX104.09x

TSHA3.90x

P/FCF Ratio

SNDXN/A

TSHAN/A

EV/FCF

SNDX-7.96x

TSHA-7.77x

PEG Ratio

SNDXN/A

TSHAN/A

Forward P/E (NTM)

SNDXN/A

TSHAN/A

Forward P/S (NTM)

SNDXN/A

TSHA664.56x

Revenue (TTM)

SNDX$252M

TSHA$5M

Revenue Growth (YoY)

SNDX222.7%

TSHA-32.3%

Forward Rev Growth

SNDX41.0%

TSHA1272.3%

Gross Margin (TTM)

SNDX95.8%

TSHA0.0%

Operating Margin (TTM)

SNDX0.0%

TSHA0.0%

EBITDA Margin (TTM)

SNDX-77.0%

TSHA-2833.6%

Net Margin (TTM)

SNDX-87.5%

TSHA-2728.0%

FCF Margin (TTM)

SNDX-87.6%

TSHA-2417.0%

Net Income (TTM)

SNDX$-221M

TSHA$-150M

FCF (TTM)

SNDX$-221M

TSHA$-133M

EPS (TTM)

SNDX-$2.48

TSHA-$0.41

ROE (TTM)

SNDX-37294.0%

TSHA-5619.0%

ROA (TTM)

SNDX-3911.0%

TSHA-4184.0%

ROIC (TTM)

SNDX-4756.0%

TSHA-4729.0%

Cash

SNDX$336M

TSHA$455M

Debt

SNDX$588M

TSHA$49M

Net Cash/Debt

SNDX$-252M

TSHA$406M

Current Ratio (TTM)

SNDX6.77x

TSHA17.76x

Quick Ratio (TTM)

SNDX6.32x

TSHA17.57x

Debt/Equity (TTM)

SNDX38.95x

TSHA0.13x

Debt/Assets (TTM)

SNDX0.0%

TSHA0.0%

Interest Coverage (TTM)

SNDXN/A

TSHAN/A

Net Debt/EBITDA (TTM)

SNDX0.00x

TSHA0.00x

Beta

SNDX0.40

TSHA1.37

52W Performance

SNDX3.0%

TSHA-11.3%

YTD Performance

SNDX-20.2%

TSHA-14.5%

% from 52W High

SNDX-33.6%

TSHA-38.5%

% from 52W Low

SNDX30.8%

TSHA21.6%

Asset Turnover (TTM)

SNDX0.45x

TSHA0.04x

FCF Yield (TTM)

SNDX-14.7%

TSHA-9.2%

Earnings Yield (TTM)

SNDX-14.7%

TSHA-10.4%

Dividend Yield (TTM)

SNDXN/A

TSHAN/A

Rule of 40

SNDX135.1

TSHA-2,449.3

EV/GP/RG

SNDX0.15

TSHAN/A

Ticker research

View SNDX research View TSHA research

Metric	SNDX Syndax Pharmaceuticals Inc	TSHA Taysha Gene Therapies Inc
Market & Valuation
Market Cap	$1.51B	$1.44B
Enterprise Value	$1.76B	$1.03B
Price	$16.99	$4.49
P/E Ratio	N/A	N/A
P/S Ratio	5.97x	261.77x
EV/Sales	6.97x	187.75x
EV/EBITDA	1,613.51x	0.00x
P/B Ratio	104.09x	3.90x
P/FCF Ratio	N/A	N/A
EV/FCF	-7.96x	-7.77x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	664.56x
Revenue & Growth
Revenue (TTM)	$252M	$5M
Revenue Growth (YoY)	222.7%	-32.3%
Forward Rev Growth	41.0%	1272.3%
Profitability
Gross Margin (TTM)	95.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-77.0%	-2833.6%
Net Margin (TTM)	-87.5%	-2728.0%
FCF Margin (TTM)	-87.6%	-2417.0%
Net Income (TTM)	$-221M	$-150M
FCF (TTM)	$-221M	$-133M
EPS (TTM)	-$2.48	-$0.41
ROE (TTM)	-37294.0%	-5619.0%
ROA (TTM)	-3911.0%	-4184.0%
ROIC (TTM)	-4756.0%	-4729.0%
Financial Health
Cash	$336M	$455M
Debt	$588M	$49M
Net Cash/Debt	$-252M	$406M
Current Ratio (TTM)	6.77x	17.76x
Quick Ratio (TTM)	6.32x	17.57x
Debt/Equity (TTM)	38.95x	0.13x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.40	1.37
52W Performance	3.0%	-11.3%
YTD Performance	-20.2%	-14.5%
% from 52W High	-33.6%	-38.5%
% from 52W Low	30.8%	21.6%
Efficiency & Yields
Asset Turnover (TTM)	0.45x	0.04x
FCF Yield (TTM)	-14.7%	-9.2%
Earnings Yield (TTM)	-14.7%	-10.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	135.1	-2,449.3
EV/GP/RG	0.15	N/A
Ticker research	View SNDX research	View TSHA research

Valuation

P/S Ratio

SNDX

5.97x

TSHA

261.77x

EV/FCF

SNDX

-7.96x

TSHA

-7.77x

Growth & revenue

Revenue Growth TTM

SNDX

222.7%

TSHA

-32.3%

Forward Revenue Growth

TSHA

1272.3%

SNDX

41.0%

Profitability & performance

Gross Margin

SNDX

95.8%

TSHA

0.0%

ROE

TSHA

-5619.0%

SNDX

-37294.0%

FCF Yield %

TSHA

-9.2%

SNDX

-14.7%

52-Week Performance

SNDX

3.0%

TSHA

-11.3%

Detailed metrics comparison

SNDX

Syndax Pharmaceuticals Inc

TSHA

Taysha Gene Therapies Inc

Market Cap

SNDX$1.51B

TSHA$1.44B

Enterprise Value

SNDX$1.76B

TSHA$1.03B

Price

SNDX$16.99

TSHA$4.49

P/E Ratio

SNDXN/A

TSHAN/A

P/S Ratio

SNDX5.97x

TSHA261.77x

EV/Sales

SNDX6.97x

TSHA187.75x

EV/EBITDA

SNDX1,613.51x

TSHA0.00x

P/B Ratio

SNDX104.09x

TSHA3.90x

P/FCF Ratio

SNDXN/A

TSHAN/A

EV/FCF

SNDX-7.96x

TSHA-7.77x

PEG Ratio

SNDXN/A

TSHAN/A

Forward P/E (NTM)

SNDXN/A

TSHAN/A

Forward P/S (NTM)

SNDXN/A

TSHA664.56x

Revenue (TTM)

SNDX$252M

TSHA$5M

Revenue Growth (YoY)

SNDX222.7%

TSHA-32.3%

Forward Rev Growth

SNDX41.0%

TSHA1272.3%

Gross Margin (TTM)

SNDX95.8%

TSHA0.0%

Operating Margin (TTM)

SNDX0.0%

TSHA0.0%

EBITDA Margin (TTM)

SNDX-77.0%

TSHA-2833.6%

Net Margin (TTM)

SNDX-87.5%

TSHA-2728.0%

FCF Margin (TTM)

SNDX-87.6%

TSHA-2417.0%

Net Income (TTM)

SNDX$-221M

TSHA$-150M

FCF (TTM)

SNDX$-221M

TSHA$-133M

EPS (TTM)

SNDX-$2.48

TSHA-$0.41

ROE (TTM)

SNDX-37294.0%

TSHA-5619.0%

ROA (TTM)

SNDX-3911.0%

TSHA-4184.0%

ROIC (TTM)

SNDX-4756.0%

TSHA-4729.0%

Cash

SNDX$336M

TSHA$455M

Debt

SNDX$588M

TSHA$49M

Net Cash/Debt

SNDX$-252M

TSHA$406M

Current Ratio (TTM)

SNDX6.77x

TSHA17.76x

Quick Ratio (TTM)

SNDX6.32x

TSHA17.57x

Debt/Equity (TTM)

SNDX38.95x

TSHA0.13x

Debt/Assets (TTM)

SNDX0.0%

TSHA0.0%

Interest Coverage (TTM)

SNDXN/A

TSHAN/A

Net Debt/EBITDA (TTM)

SNDX0.00x

TSHA0.00x

Beta

SNDX0.40

TSHA1.37

52W Performance

SNDX3.0%

TSHA-11.3%

YTD Performance

SNDX-20.2%

TSHA-14.5%

% from 52W High

SNDX-33.6%

TSHA-38.5%

% from 52W Low

SNDX30.8%

TSHA21.6%

Asset Turnover (TTM)

SNDX0.45x

TSHA0.04x

FCF Yield (TTM)

SNDX-14.7%

TSHA-9.2%

Earnings Yield (TTM)

SNDX-14.7%

TSHA-10.4%

Dividend Yield (TTM)

SNDXN/A

TSHAN/A

Rule of 40

SNDX135.1

TSHA-2,449.3

EV/GP/RG

SNDX0.15

TSHAN/A

Ticker research

View SNDX research View TSHA research

Metric	SNDX Syndax Pharmaceuticals Inc	TSHA Taysha Gene Therapies Inc
Market & Valuation
Market Cap	$1.51B	$1.44B
Enterprise Value	$1.76B	$1.03B
Price	$16.99	$4.49
P/E Ratio	N/A	N/A
P/S Ratio	5.97x	261.77x
EV/Sales	6.97x	187.75x
EV/EBITDA	1,613.51x	0.00x
P/B Ratio	104.09x	3.90x
P/FCF Ratio	N/A	N/A
EV/FCF	-7.96x	-7.77x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	664.56x
Revenue & Growth
Revenue (TTM)	$252M	$5M
Revenue Growth (YoY)	222.7%	-32.3%
Forward Rev Growth	41.0%	1272.3%
Profitability
Gross Margin (TTM)	95.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-77.0%	-2833.6%
Net Margin (TTM)	-87.5%	-2728.0%
FCF Margin (TTM)	-87.6%	-2417.0%
Net Income (TTM)	$-221M	$-150M
FCF (TTM)	$-221M	$-133M
EPS (TTM)	-$2.48	-$0.41
ROE (TTM)	-37294.0%	-5619.0%
ROA (TTM)	-3911.0%	-4184.0%
ROIC (TTM)	-4756.0%	-4729.0%
Financial Health
Cash	$336M	$455M
Debt	$588M	$49M
Net Cash/Debt	$-252M	$406M
Current Ratio (TTM)	6.77x	17.76x
Quick Ratio (TTM)	6.32x	17.57x
Debt/Equity (TTM)	38.95x	0.13x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.40	1.37
52W Performance	3.0%	-11.3%
YTD Performance	-20.2%	-14.5%
% from 52W High	-33.6%	-38.5%
% from 52W Low	30.8%	21.6%
Efficiency & Yields
Asset Turnover (TTM)	0.45x	0.04x
FCF Yield (TTM)	-14.7%	-9.2%
Earnings Yield (TTM)	-14.7%	-10.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	135.1	-2,449.3
EV/GP/RG	0.15	N/A
Ticker research	View SNDX research	View TSHA research